

Broadly reactive SARS-CoV-2 entry inhibitor derived from Chinese medicine

September 23 2022



The research team of Dr Chen Jianping (right) and Dr Liu Li (left) discovered a broadly reactive SARS-CoV-2 entry inhibitor derived from Chinese medicine.

A research team comprising members of the School of Chinese Medicine, AIDS Institute, Department of Microbiology, School of

Clinical Medicine and State Key Laboratory for Emerging Infectious Diseases, the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) have discovered a natural product SSP derived from a Chinese herb *Spatholobus Suberectus* Dunn that demonstrated broad antiviral activities against SARS-CoV-1, SARS-CoV-2, influenza, and HIV-1 as an entry blocker.

Critically, it shows comparable activities against all major pandemic strains of SARS-CoV-2 variants of concern tested. Since SSP has been prepared in a cost-effective manner under safe manufacturer practices and do not cause toxicity in animals, it has great potential to be developed into a preventive drug for eliminating the spread of SARS-CoV-2. The findings are now published online in the journal *Phytotherapy Research*.

The world suffers from continuous waves of SARS-CoV-2 caused by newly emerged viral variants that can evade vaccine-induced immune protection. The development of novel vaccines against escape viral variants is far behind the speed of their evolution. Therefore, identifying alternative interventions to eliminate the continuous spread of SARS-CoV-2 variants is necessary. To this end, the search for viral entry inhibitors with a broad spectrum of activities and [cost-effectiveness](#) becomes essential for the prevention of SARS-CoV-2 variants.

The HKUMed research team screened extracts derived from a Chinese herb named *Spatholobus Suberectus* Dunn (SSD) against diverse types of viruses including SARS-CoV-1, SARS-CoV-2, influenza H5N1 and HIV-1. They found that the SSD-derived extract (SSP) exhibits broad activities against all the aforesaid viruses. Subsequent studies confirmed that SSP has comparable potency against SARS-CoV-2 variants of concern including alpha (B.1.1.7), beta (B.1.351), gamma (P1), delta (B.1.617.2), and omicron (BA.1, BA.2 and BA.4/5). SSP blocked both SARS-CoV-2 spike glycoprotein and the host ACE2 receptor. Critically,

intranasal administration of SSP significantly reduced live omicron BA.2 challenge in human ACE2-transgenic mice. Since SSP has been GMP-produced at low costs, it has great potential to be developed as an intranasal drug for the prevention and treatment of SARS-CoV-2 infection.

"We have been studying this Chinese medicine for over 20 years. SSP acts as a potential antiviral agent, making it useful in combating the COVID-19 pandemic. Since there are few effective preventive drugs in the world, SSP is a new antiviral agent that can be developed to prevent COVID-19," explained Dr. Chen Jianping, Principal Lecturer of School of Chinese Medicine, HKUMed. After a rodent model investigation comparing low and high dose administrations of SSP, no toxicity was caused, thus considered safe.

"These findings suggest that SSP may have broad antiviral activities against different types of respiratory viral infections," said Dr. Liu Li, Research Assistant Professor of the AIDS Institute and Department of Microbiology, School of Clinical Medicine, HKUMed, who made the breakthrough discovery. "Since different GMP-batches show consistent antiviral activities, we are confident of the clinical development of SSP."

More information: Qingqing Liu et al, Broad-spectrum antiviral activity of *Spatholobus suberectus* Dunn against SARS-CoV -2, SARS-CoV -1, H5N1, and other enveloped viruses, *Phytotherapy Research* (2022). [DOI: 10.1002/ptr.7452](https://doi.org/10.1002/ptr.7452)

Provided by The University of Hong Kong

Citation: Broadly reactive SARS-CoV-2 entry inhibitor derived from Chinese medicine (2022, September 23) retrieved 26 April 2024 from <https://medicalxpress.com/news/2022-09-broadly->

[reactive-sars-cov-entry-inhibitor.html](https://www.medicalpress.com/entry-inhibitor.html)

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.